PubMed COVID-19 Clinical Care
891 - 900 of 1332 results found
Novel neutralizing mouse-human chimeric monoclonal antibodies against the SARS-CoV-2 receptor binding domain
Description
Introduction. Neutralizing antibodies have been widely used for the prophylaxis and treatment of COVID-19.Hypothesis. The major target for these neutralizing antibodies is the receptor-binding domain (RBD) of the viral spike protein.Aim. In the
New emerging SARS-CoV-2 variants and antiviral agents
Description
No abstract
Nonstationary time series forecasting using optimized-EVDHM-ARIMA for COVID-19
Description
The Coronavirus (COVID-19) outbreak swept the world, infected millions of people, and caused many deaths. Multiple COVID-19 variations have been discovered since the initial case in December 2019, indicating that COVID-19 is highly mutable. COVID-19
Neural basis underlying the sense of coherence in medical professionals revealed by the fractional amplitude of low-frequency fluctuations
Description
Although mitigating burnout has long been a pressing issue in healthcare, recent global disasters, including the COVID-19 pandemic and wars, have exacerbated this problem. Medical professionals are frequently exposed to diverse job-induced distress
New COVID jabs are coming - who should get them?
Description
No abstract
NAUNEHAL; Integrated immunization and MNCH interventions: A quasi-experimental study-Protocol
Description
INTRODUCTION: Great improvements in the health of newborns, children, and women in Pakistan are needed. A large body of literature has demonstrated that the majority of maternal, newborn, and child deaths are preventable with essential health
Non-communicable chronic diseases: Mortality of older adult citizens in Brazil and Italy before the Covid-19 pandemic
Description
The purpose of this study was to outline the main non-communicable chronic diseases that led older people to death in Brazil and Italy before the SARS-CoV-2 pandemic according to age gaps and region of residence. This study has identified that the
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
Description
CONCLUSIONS: rNAPc2 treatment in hospitalized patients with COVID-19 was well tolerated without excess bleeding or serious adverse events but did not significantly reduce D-dimer more than heparin at day 8.
